-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reviewing Alpha Tau Medical (NASDAQ:DRTS) and Anika Therapeutics (NASDAQ:ANIK)
Reviewing Alpha Tau Medical (NASDAQ:DRTS) and Anika Therapeutics (NASDAQ:ANIK)
Alpha Tau Medical (NASDAQ:DRTS – Get Rating) and Anika Therapeutics (NASDAQ:ANIK – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Alpha Tau Medical and Anika Therapeutics, as reported by MarketBeat.com.
Get Alpha Tau Medical alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Tau Medical | 0 | 0 | 3 | 0 | 3.00 |
| Anika Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Alpha Tau Medical currently has a consensus target price of $17.67, indicating a potential upside of 334.07%. Anika Therapeutics has a consensus target price of $28.50, indicating a potential downside of 5.22%. Given Alpha Tau Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Alpha Tau Medical is more favorable than Anika Therapeutics.
Earnings and Valuation
This table compares Alpha Tau Medical and Anika Therapeutics' top-line revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Tau Medical | N/A | N/A | -$27.27 million | N/A | N/A |
| Anika Therapeutics | $147.79 million | 2.97 | $4.13 million | ($1.09) | -27.59 |
Anika Therapeutics has higher revenue and earnings than Alpha Tau Medical.
Profitability
This table compares Alpha Tau Medical and Anika Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Tau Medical | N/A | -49.72% | -33.76% |
| Anika Therapeutics | -10.33% | -2.49% | -2.05% |
Risk & Volatility
Alpha Tau Medical has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Institutional and Insider Ownership
1.0% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 91.6% of Anika Therapeutics shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by company insiders. Comparatively, 3.0% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Anika Therapeutics beats Alpha Tau Medical on 6 of the 11 factors compared between the two stocks.
About Alpha Tau Medical
(Get Rating)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
About Anika Therapeutics
(Get Rating)
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
Alpha Tau Medical (NASDAQ:DRTS – Get Rating) and Anika Therapeutics (NASDAQ:ANIK – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.
阿尔法头医疗(纳斯达克：DRTS-GET评级)和安妮卡治疗(纳斯达克：ANIK-GET评级)都是小盘医疗公司，但哪只股票更好？我们将根据两家公司的估值、股息、分析师建议、机构所有权、收益、风险和盈利能力的强弱对它们进行比较。
Analyst Recommendations
分析师建议
This is a breakdown of current ratings and recommmendations for Alpha Tau Medical and Anika Therapeutics, as reported by MarketBeat.com.
据MarketBeat.com报道，这是Alpha Tau Medical和Anika Treeutics目前的评级和推荐细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Tau Medical | 0 | 0 | 3 | 0 | 3.00 |
| Anika Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Alpha Tau医疗公司 | 0 | 0 | 3 | 0 | 3.00 |
| 安妮卡治疗公司 | 0 | 1 | 1 | 0 | 2.50 |
Alpha Tau Medical currently has a consensus target price of $17.67, indicating a potential upside of 334.07%. Anika Therapeutics has a consensus target price of $28.50, indicating a potential downside of 5.22%. Given Alpha Tau Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Alpha Tau Medical is more favorable than Anika Therapeutics.
Alpha Tau Medical目前的共识目标价为17.67美元，表明潜在上行334.07%。Anika Treeutics的共识目标价为28.50美元，表明潜在下跌5.22%。鉴于Alpha Tau Medical更强的共识评级和更高的可能上行空间，股票分析师显然认为Alpha Tau Medical比Anika Treeutics更有利。
Earnings and Valuation
收益和估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Tau Medical | N/A | N/A | -$27.27 million | N/A | N/A |
| Anika Therapeutics | $147.79 million | 2.97 | $4.13 million | ($1.09) | -27.59 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Alpha Tau医疗公司 | 不适用 | 不适用 | -2,727万元 | 不适用 | 不适用 |
| 安妮卡治疗公司 | 1.4779亿美元 | 2.97 | 413万美元 | ($1.09) | -27.59 |
Anika Therapeutics has higher revenue and earnings than Alpha Tau Medical.
Anika Treateutics的收入和收益高于Alpha Tau Medical。
Profitability
盈利能力
This table compares Alpha Tau Medical and Anika Therapeutics' net margins, return on equity and return on assets.
此表比较了Alpha Tau Medical和Anika Treeutics的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Tau Medical | N/A | -49.72% | -33.76% |
| Anika Therapeutics | -10.33% | -2.49% | -2.05% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Alpha Tau医疗公司 | 不适用 | -49.72% | -33.76% |
| 安妮卡治疗公司 | -10.33% | -2.49% | -2.05% |
Risk & Volatility
风险与波动性
Alpha Tau Medical has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Alpha Tau Medical的贝塔系数为0.81，这意味着其股价的波动性比标准普尔500指数低19%。相比之下，Anika Treeutics的贝塔系数为0.97，这意味着其股价的波动性比标准普尔500指数低3%。
Institutional and Insider Ownership
机构和内部人持股
1.0% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 91.6% of Anika Therapeutics shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by company insiders. Comparatively, 3.0% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Alpha Tau Medical 1.0%的股份由机构投资者持有。相比之下，安妮卡治疗公司91.6%的股份由机构投资者持有。Alpha Tau Medical 39.5%的股份由公司内部人士持有。相比之下，安妮卡治疗公司3.0%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、大型基金经理和对冲基金相信，从长期来看，一只股票的表现将好于大盘。
Summary
摘要
Anika Therapeutics beats Alpha Tau Medical on 6 of the 11 factors compared between the two stocks.
在两只股票之间的11个因素中，Anika Treeutics在6个因素上击败了Alpha Tau Medical。
About Alpha Tau Medical
关于Alpha Tau Medical
(Get Rating)
(获取评级)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Alpha Tau医疗有限公司是一家临床阶段的肿瘤治疗公司，在以色列和美国从事用于治疗实体癌症的扩散阿尔法放射疗法(Alpha DART)的研究、开发和商业化。其Alpha-DART技术用于皮肤癌、口腔癌、胰腺癌和乳腺癌的临床试验；以及肝细胞癌、多形性胶质母细胞瘤、肺癌等的临床前研究。该公司成立于2015年，总部设在以色列耶路撒冷。
About Anika Therapeutics
关于Anika Treateutics
(Get Rating)
(获取评级)
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
Anika Treateutics，Inc.是一家整形外科和再生药物公司，开发、制造和销售用于疼痛管理、组织再生和伤口愈合的治疗产品。它的产品是基于透明质酸，这是一种存在于全身的天然化学物质，生物相容性高的聚合物。它提供的治疗产品包括骨科、真皮、眼科、外科、眼科和兽医。该公司成立于1992年，总部设在马萨诸塞州的贝德福德。
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
获得Alpha Tau医学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Alpha Tau Medical和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧